Latest

• Blood collection tube and RNA purification method recommendations for extracellular RNA transcriptome profiling
• Congratulations to Dr. Deleu
• Extracellular RNA in liquid biopsies: entering a new era for cancer treatment monitoring?
• Longitudinal evaluation of serum microRNAs as biomarkers for neuroblastoma burden and therapeutic p53 reactivation
• Digital PCR-based evaluation of nucleic acid extraction kit performance for the co-purification of cell-free DNA and RNA
• Performance evaluation of RNA purification kits and blood collection tubes in the Extracellular RNA Quality Control (exRNAQC) study
• Whole transcriptome profiling of liquid biopsies from tumour xenografted mouse models enables specific monitoring of tumour-derived extracellular RNA
• Cost-effective and robust genotyping using double-mismatch allele-specific quantitative PCR
• Circulating microRNA biomarkers for metastatic disease in neuroblastoma patients
• MicroRNA Expression Analysis Using Small RNA Sequencing Discovery and RT-qPCR-Based Validation
• Dual targeting of MDM2 and BCL2 as a therapeutic strategy in neuroblastoma
• Depletion of tRNA-halves enables effective small RNA sequencing of low-input murine serum samples
• Inhibition of CDK4/6 as a novel therapeutic option for neuroblastoma
• Identification of miRNAs contributing to neuroblastoma chemoresistance
• Genome wide expression profiling of p53 regulated miRNAs in neuroblastoma
• CASP8 SNP D302H (rs1045485) Is Associated with Worse Survival in MYCN-Amplified Neuroblastoma Patients
• Characterization of the p53 network and new therapeutic opportunities in neuroblastoma
• Lack of association betweenMDM2promoter SNP309 and clinical outcome in patients with neuroblastoma
• Pharmacologic activation of wild-type p53 by nutlin therapy in childhood cancer
• Effective Alu Repeat Based RT-Qpcr Normalization in Cancer Cell Perturbation Experiments
• Focal DNA Copy Number Changes in Neuroblastoma Target MYCN Regulated Genes
• Genome-wide promoter methylation analysis in neuroblastoma identifies prognostic methylation biomarkers
• EVI1-mediated down regulation of MIR449A is essential for the survival of EVI1 positive leukaemic cells
• New options for molecular therapy of neuroblastoma: from p53 to gene therapy
• Antitumor Activity of the Selective MDM2 Antagonist Nutlin-3 Against Chemoresistant Neuroblastoma With Wild-Type p53
• The emerging molecular pathogenesis of neuroblastoma: implications for improved risk assessment and targeted therapy